You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

CLINICAL TRIALS PROFILE FOR SULINDAC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Sulindac

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003365 ↗ Sulindac and Plant Compounds in Preventing Colon Cancer Terminated National Cancer Institute (NCI) N/A 1996-08-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of sulindac may be an effective way to prevent colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may prevent the development of colon cancer. PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin, and quercetin in preventing colon cancer.
NCT00003365 ↗ Sulindac and Plant Compounds in Preventing Colon Cancer Terminated University of Medicine and Dentistry of New Jersey N/A 1996-08-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of sulindac may be an effective way to prevent colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may prevent the development of colon cancer. PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin, and quercetin in preventing colon cancer.
NCT00005882 ↗ Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Completed Chao Family Comprehensive Cancer Center Phase 3 1998-07-01 This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
NCT00005882 ↗ Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Completed National Cancer Institute (NCI) Phase 3 1998-07-01 This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
NCT00005882 ↗ Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Completed University of California, Irvine Phase 3 1998-07-01 This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
NCT00037609 ↗ Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Completed Cell Pathways Phase 1/Phase 2 2001-01-01 The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the biological activity of exisulind. The primary objective of the Phase II part of this study is to assess the anti-tumor activity of this combination therapy measured by objective tumor response. Secondary end points also assessed will be toxicity of therapy, duration of response and time to progression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sulindac

Condition Name

Condition Name for Sulindac
Intervention Trials
Precancerous Condition 5
Colorectal Cancer 4
Familial Adenomatous Polyposis 3
Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sulindac
Intervention Trials
Colorectal Neoplasms 10
Precancerous Conditions 6
Nasopharyngeal Neoplasms 5
Adenomatous Polyposis Coli 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sulindac

Trials by Country

Trials by Country for Sulindac
Location Trials
United States 102
Canada 2
Netherlands 2
United Kingdom 2
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sulindac
Location Trials
California 7
Massachusetts 7
New York 7
Arizona 6
Minnesota 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sulindac

Clinical Trial Phase

Clinical Trial Phase for Sulindac
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 18
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sulindac
Clinical Trial Phase Trials
Completed 17
Terminated 6
Recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sulindac

Sponsor Name

Sponsor Name for Sulindac
Sponsor Trials
National Cancer Institute (NCI) 16
Cancer Prevention Pharmaceuticals, Inc. 4
Massachusetts General Hospital 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sulindac
Sponsor Trials
Other 38
NIH 17
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.